Skip to main content
CING
NASDAQ Life Sciences

Cingulate Inc. Establishes $100M At-The-Market Offering and Secures Shareholder Approval for Prior Issuances

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$6.58
Mkt Cap
$78.028M
52W Low
$3.2
52W High
$11.89
Market data snapshot near publication time

summarizeSummary

Cingulate Inc. launched a new $100 million At-The-Market offering to raise capital, a highly dilutive move for a company facing a going concern, while also securing shareholder approval for prior stock issuances.


check_boxKey Events

  • Establishes $100M At-The-Market (ATM) Offering

    Cingulate Inc. entered into an ATM Sales Agreement to sell up to $100,000,000 of common stock. This program allows the company to sell shares into the market over time, providing a significant source of capital but also representing substantial potential dilution for existing shareholders, given the company's market capitalization.

  • Shareholders Approve Prior Stock Issuances

    At a Special Meeting, stockholders approved the issuance of common stock upon conversion of Series A Convertible Preferred Stock and/or exercise of warrants, as per a securities purchase agreement dated January 27, 2026. This vote was necessary for Nasdaq compliance to enable the company to complete a previously announced financing.


auto_awesomeAnalysis

Cingulate Inc. has established a new At-The-Market (ATM) Sales Agreement, enabling it to sell up to $100 million of common stock from time to time. This represents a substantial capital raise, significantly exceeding the company's current market capitalization, and indicates a critical need for funding. The ATM program utilizes the universal shelf registration statement (File No. 333-292680) that was recently amended on March 23, 2026. This aggressive financing effort follows the company's recent 10-K filing on March 18, 2026, which disclosed a going concern warning and a short cash runway, making this ATM a vital, albeit highly dilutive, mechanism for extending its operational runway. Additionally, shareholders approved the issuance of common stock related to a prior financing agreement from January 27, 2026, which involved Series A Convertible Preferred Stock and warrants. This approval is a necessary compliance step to enable the company to fulfill its obligations under that previous agreement.

At the time of this filing, CING was trading at $6.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78M. The 52-week trading range was $3.20 to $11.89. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed CING - Latest Insights

CING
Apr 28, 2026, 4:24 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Apr 14, 2026, 5:26 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 27, 2026, 4:01 PM EDT
Filing Type: 424B3
Importance Score:
8
CING
Mar 26, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
CING
Mar 24, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
9
CING
Mar 24, 2026, 5:13 PM EDT
Filing Type: 424B3
Importance Score:
9
CING
Mar 19, 2026, 6:00 PM EDT
Filing Type: S-3
Importance Score:
8
CING
Mar 18, 2026, 4:30 PM EDT
Filing Type: DEFA14A
Importance Score:
8
CING
Mar 18, 2026, 8:13 AM EDT
Filing Type: 10-K
Importance Score:
9
CING
Mar 18, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9